Hemispherx Biopharma (HEB) Announces Plans To File For Regulatory Approval Of Ampligen® To Treat Chronic Fatigue Syndrome (CFS) In Three Additional Latin America Countries
3/11/2014 9:20:31 AM
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning on making applications in Chile, Peru and Uruguay for regulatory approval of Ampligen® to treat CFS.
Help employers find you! Check out all the jobs and post your resume.
comments powered by